Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer - Test2 - elhamkhani - TriplyDB

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

http://www.wikidata.org/entity/Q24632855

about

Site-specific functionalization of proteins and their applications to therapeutic antibodies Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics.Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy.Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer Antibody Therapeutics in Oncology.CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.Ado-trastuzumab emtansine and radium 223 dichloride.Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).Pharmacokinetic considerations for antibody drug conjugates.ADME of antibody-maytansinoid conjugates Drug-conjugated antibodies for the treatment of cancer.Trastuzumab emtansine in breast cancer.Trastuzumab emtansine: first global approval.Strategies to address drug interaction potential for antibody-drug conjugates in clinical development.Trends in cancer-targeted antibody-drug conjugates.Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.

P2860

Q26830699-E9AA9EBB-980D-4EC7-9D69-0CA4185ABAFE Q26830923-9B53A24F-B993-40EC-9F3A-963C992266AE Q27003258-806A90E7-C610-44BF-9AD7-1F81CC524BC2 Q27015048-E8E963F5-9B31-4E80-839F-957E95AACA38 Q27303016-F53B481A-B7F7-44AE-8281-02BB908C2E99 Q28067696-0C868606-C290-459E-B3AC-8A9F1EAE5DB8 Q33409083-7646BAE8-79B7-45DC-9E35-F262F2659AC0 Q33414335-9424AAA6-6F15-4093-A3B2-ED6B05CC81B8 Q33415375-0F461017-1C47-49B3-B2A1-BE1399CD259C Q33430299-C84293A5-C846-4372-8568-2F01265D0529 Q33430735-7177DF66-862D-4D2F-A411-8EC8DA8F12B4 Q33433942-DD323F97-705C-43D5-82C8-B07500FD135B Q33954595-2CDCEE5F-7319-4672-A5E8-10F7C9D0D907 Q34045119-8F8D014C-D082-4E98-8D9D-86E6377A8E45 Q34099745-11017373-836E-4673-B130-3FF977BA7431 Q34389275-D819A2FB-6C09-4B52-A078-2337597A7D7E Q34434128-2AF2DB92-D64F-467B-8B5F-C48966FFDA50 Q35068522-2E810DEE-FD14-4306-9F12-D8E0FDECC8DA Q35652998-577C1F9D-FB02-46A5-84CE-0C3EA1990ACA Q36097775-68628C11-046A-4D8A-A7BA-39739C7715A2 Q36273796-209FC506-BADA-4010-B546-D1BFD8D614A5 Q36585636-30163BA8-459D-4226-809E-13875A8EF666 Q36653094-8B631A32-E3B7-4B65-AE7A-26E3B8054BDB Q36791878-DC786906-E1CE-4F9A-9A99-C8B6D5B29D0F Q37184796-C063E50F-F473-48FB-B2BD-9F989D951C4E Q37329842-B77E7F7D-A5FF-4970-9F3B-23411956102E Q37378269-3EAB3BD8-B68D-4605-8D81-F82C9ABE753C Q37387449-139AC105-3CDB-4DB8-86B7-7ECFFCA9F6BF Q37580443-CF608636-B321-40F6-9DE5-BD7F2E2AB040 Q37600390-D127261D-BABE-4EBA-A3D7-0A53E904B056 Q37680178-F59FC544-E318-4B05-9F76-6656FD30FD5E Q38022192-5FB8C5F2-59E1-43AA-B7BF-E860EE32477A Q38033114-149DB940-C513-47D6-A555-D79FC8367E2C Q38061647-9D9489B6-A948-4642-89B7-79D445021FF6 Q38088038-20CA5530-6D57-4B1B-8657-63B61BEAFFE5 Q38101890-C2279E08-BB82-46E6-81D2-E4B641F7B500 Q38103883-08C319E0-82EC-49F7-81D9-6ECA787F8D09 Q38162127-83E4059D-7814-4055-865F-487F9735B697 Q38198573-E83FF79D-FF3D-4FE3-9312-8964DA390384 Q38204975-A154E7E1-B402-4C19-9E8B-E68D784E0DDE

P2860

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

http://www.wikidata.org/entity/Q24632855

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@ast

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@en

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@nl

type

label

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@ast

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@en

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@nl

prefLabel

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@ast

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@en

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@nl

P1433

Q24632855-D791716B-9037-42DD-A5AA-834CC907C02F

P1476

Q24632855-A86BDCD0-E603-48D5-B3C8-D3759B573FBC

P2093

Q24632855-15019234-5952-4BB5-AB7B-1320B1A5BDC0

Q24632855-19097829-6647-4CFB-85B8-06506C8AC989

Q24632855-2215786A-7B3A-4611-A2D5-D1952AFD4038

Q24632855-268083EA-3492-4C03-9462-BD178FEE0B4D

Q24632855-29F04A47-7382-402B-9EF4-423C9AF5B4C4

Q24632855-5396D391-20F9-452D-B828-09F25CA33A13

Q24632855-62094243-9DA9-4F56-97E3-91A3C59A31B2

Q24632855-625CD4CC-3AB3-444E-BDA4-17EE267FA986

Q24632855-73C744FA-3D1A-4337-BD1D-BC4D5673882C

Q24632855-A9346273-67E2-4CB4-8A1F-6FDC32D169D4

P2860

Q24632855-0BA921E2-E973-4BE1-947E-BF82C6763BA3

Q24632855-1DDC24FF-DCF8-4E58-B60F-043A85031180

Q24632855-29145A23-38F3-4B47-9F7D-B1DD84BB5ACC

Q24632855-307C157E-8F44-420A-AD0D-709D0C414B1E

Q24632855-394A6B11-F622-420F-9623-56A5DF064EA5

Q24632855-6AADD28B-B3B4-4CE7-8DA5-A6FAFD39E932

Q24632855-6D61B9C2-626A-4FB2-8BE3-67C3F02F6435

Q24632855-7573FEBF-5ABB-442D-84BF-37FD61A3092E

Q24632855-78BB4C9A-9B73-4458-85D3-AA33392891FB

Q24632855-A1B2D682-D589-4A7B-B021-D30648DD22E9

P2888

Q24632855-E2B14146-B6EE-4245-BF59-78FDA84B913B

P304

Q24632855-625E07BF-9304-416E-B47C-76348F91684B

P31

Q24632855-3462173D-1DE9-4A71-8530-78B882B2774F

P3181

Q24632855-653605B8-6769-4D3C-B55E-FA3A955DC410

P356

Q24632855-4292AC85-90C6-40AA-9E71-55EA3F7550B5

P407

Q24632855-87B026CA-9EEF-4DB4-B2E0-C68AC23BE33B

P433

Q24632855-08A0F662-7F84-40FE-9E3C-F563ADFCBEF1

P478

Q24632855-8E96F865-7596-424A-B729-A7A34D8E7FA8

P577

Q24632855-7F07E982-7114-443C-8829-C8479335907D

P5875

Q24632855-1E88C84E-62D8-45BA-A877-5714957265CD

P6179

Q24632855-238B6935-EF2F-4B1C-9F53-A9F99C44DD55

P698

Q24632855-6A35DCDE-D41E-4A72-8626-93A041C8C1D7

P921

Q24632855-117B03C9-49DE-48E6-A36A-DB6AD06F0739

Q24632855-8FE797DA-AED4-486E-BDFE-C49282B8D8EB

P932

Q24632855-B9AF09F7-6EAA-4121-AE22-D4C38862A828

P3181

P356

S00280-011-1817-3

P1433

Cancer Chemotherapy and Pharmacology

P1476

Clinical pharmacology of trast ...... atment of HER2-positive cancer

@en

P2093

Amita Joshi

http://www.w3.org/2001/XMLSchema#string

Barbara Tong

http://www.w3.org/2001/XMLSchema#string

Bei Wang

http://www.w3.org/2001/XMLSchema#string

Charles L Vogel

http://www.w3.org/2001/XMLSchema#string

Dan Lu

http://www.w3.org/2001/XMLSchema#string

Howard A Burris Iii

http://www.w3.org/2001/XMLSchema#string

Ian E Krop

http://www.w3.org/2001/XMLSchema#string

Joo-Hee Yi

http://www.w3.org/2001/XMLSchema#string

Manish Gupta

http://www.w3.org/2001/XMLSchema#string

Ola Saad

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

Arming antibodies: prospects and challenges for immunoconjugates.

Immunoconjugates containing novel maytansinoids: promising anticancer drugs.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Recent developments in the maytansinoid antitumor agents.

P2888

s00280-011-1817-3

P304

1229-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3160611

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S00280-011-1817-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221771722

http://www.w3.org/2001/XMLSchema#string

P6179

1031527271

http://www.w3.org/2001/XMLSchema#string

P698

22271209

http://www.w3.org/2001/XMLSchema#string

P921

P932

3337408

http://www.w3.org/2001/XMLSchema#string